Previous Close | 1.1500 |
Open | 1.2300 |
Bid | 1.3400 x 4000 |
Ask | 1.3600 x 4000 |
Day's Range | 1.2100 - 1.4400 |
52 Week Range | 0.3010 - 2.9300 |
Volume | |
Avg. Volume | 5,297,429 |
Market Cap | 147.018M |
Beta (5Y Monthly) | 0.60 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.3560 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 699.23 |
LONDON and MOUNTAIN VIEW, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that it has received a written notification (the “Notification Letter”) from the Listing Qualifications Department of the Nasdaq Stock Market, LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement set forth in
NEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of:NIO, Inc. (NYSE:NIO), NexTech AR Solutions (OTC: NEXCF) (CSE: NTAR), Mereo BioPharma (NASDAQ: MREO), AI/ML Innovations (OTC: AIMLF) (CSE: AIML). Today’s emerging technologies and lifestyle megatrends are creating billion dollar opportunities for disruptive innovation in how we live, work and play. Wall Street Repo
Shares of Mereo BioPharma (MREO) surge after reports suggest that AstraZeneca (AZN) is interested in acquiring it.